The Transmitter, Год журнала: 2023, Номер unknown
Опубликована: Янв. 1, 2023
The Transmitter, Год журнала: 2023, Номер unknown
Опубликована: Янв. 1, 2023
Brain Behavior and Immunity, Год журнала: 2024, Номер 118, С. 398 - 407
Опубликована: Март 8, 2024
Язык: Английский
Процитировано
1Comprehensive Psychoneuroendocrinology, Год журнала: 2024, Номер 19, С. 100236 - 100236
Опубликована: Апрель 27, 2024
Neuroendocrine analyses of posttraumatic stress disorder (PTSD) have generally focused on hypothalamic-pituitary-adrenal (HPA) axis alterations. In the present analyses, we examine two additional neuroendocrine factors that been previously implicated in biological responses: oxytocin (OT) and arginine vasopressin (AVP). Here examined basal neuropeptide status military veterans clinically diagnosed with PTSD (n = 29) non-traumatized comparison groups previous exposure 11 SWAT trainees n 21 ultramarathon runners). patients showed low levels plasma OT high AVP. The ratio AVP/OT robustly related to status, emerged as a statistically plausible mediator relationships between number personal traumatic experiences subsequent symptom burden. Over course behavioral therapy for PTSD, measures significant but modest normalization. Plasma cortisol were not different among three groups. This study suggests ratios may represent predictor severe well potential treatment response biomarker.
Язык: Английский
Процитировано
1Neuropsychopharmacology, Год журнала: 2024, Номер 49(12), С. 1934 - 1946
Опубликована: Июль 17, 2024
Autism Spectrum Disorders (ASD) are neurodevelopmental disorders whose diagnosis relies on deficient social interaction and communication together with repetitive behaviours. Multiple studies have highlighted the potential of oxytocin (OT) to ameliorate behavioural abnormalities in animal models subjects ASD. Clinical trials, however, yielded disappointing results. Our study aimed at assessing effects different regimens OT administration Oprm1 null mouse model We assessed intranasal injected once doses (0.15, 0.3, 0.6 IU) time points (5, 15, 30 min) following administration, or chronically, ASD-related behaviours (social preference, stereotypies, anxiety, nociception)
Язык: Английский
Процитировано
1bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown
Опубликована: Март 10, 2024
Abstract Autism Spectrum Disorders (ASD) are neurodevelopmental disorders whose diagnosis relies on deficient social interaction and communication together with repetitive behaviours. Multiple studies have highlighted the potential of oxytocin (OT) to ameliorate behavioural abnormalities in animal models subjects ASD. Clinical trials, however, yielded disappointing results. Our study aimed at challenging hypotheses accounting for such negative results by assessing effects different regimens OT administration Oprm1 null mouse model We assessed intranasal injected once doses time points following administration, or chronically, ASD-related behaviours +/+ -/- mice. then tested whether pairing injection experience would influence its outcome ASD-like core symptoms, measured gene expression several regions reward/social circuit. Acute improved behaviour mice a moderate dose (0.3 IU) shortly after (5 min). Effects non-social were limited. Chronic this maintained beneficial but was deleterious wild-type Finally, improvements greater longer lasting when administered context, while vasopressin receptor genes, as well marker genes striatal projection neurons, suppressed. highlight importance considering dosage context evaluating treatment Highlights limited mutant Oxytocin triggers longer-lasting within suppresses own key neuron markers
Язык: Английский
Процитировано
0Peptides, Год журнала: 2024, Номер 182, С. 171301 - 171301
Опубликована: Окт. 10, 2024
Язык: Английский
Процитировано
0The Transmitter, Год журнала: 2023, Номер unknown
Опубликована: Янв. 1, 2023
Процитировано
0